Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
STIMATE (NEEDS NO REFRIGERATION) vs DIAPID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that increases cyclic AMP levels in renal collecting duct cells, enhancing water reabsorption and concentrating urine. It also raises plasma levels of von Willebrand factor and factor VIII by stimulating release from endothelial stores.
Diapid (lypressin) is a synthetic analog of vasopressin that acts as an antidiuretic by increasing water reabsorption in the renal collecting ducts via V2 receptor activation. It also has mild vasopressor activity via V1 receptor stimulation.
Central diabetes insipidus (approved by FDA),Primary nocturnal enuresis (approved by FDA),Hemophilia A with factor VIII deficiency (off-label),von Willebrand disease (type I, some type II and III) (off-label),Nocturia in multiple sclerosis (off-label),Uremic bleeding (off-label)
Diabetes insipidus (central),Nocturnal enuresis (off-label)
Intranasal: 1 spray (1.5 mg) into one nostril; may repeat once after 30-60 minutes if needed. Not to exceed 2 doses per bleeding episode.
Intravenous bolus of 20 mg followed by 20-40 mg every 2-4 hours as needed. Maximum single dose: 80 mg.
Terminal elimination half-life is 2-4 hours (mean 3 hours), which supports a dosing interval of 2-4 hours in clinical use.
Terminal elimination half-life is 1.5-3 hours; clinically significant in patients with renal impairment, requiring dose adjustment
Primarily metabolized by the liver via reduction of the disulfide bridge by glutathione, and to a lesser extent by proteolysis. The metabolite is not active. Excretion: renal (filtration and tubular secretion).
Lypressin is rapidly metabolized by peptidases in the liver and kidneys, with a half-life of approximately 15 minutes.
Renal excretion of intact drug and metabolites accounts for >90% of elimination; biliary/fecal excretion is minimal (<5%).
Primarily renal excretion as unchanged drug (80-90%); minor biliary/fecal elimination (<10%)
Plasma protein binding is approximately 50-60%, primarily to albumin and to a lesser extent alpha-1 acid glycoprotein.
20-30% bound to plasma proteins
Volume of distribution is 0.2-0.4 L/kg, indicating moderate distribution into total body water and some tissue binding.
0.6-0.8 L/kg; distributes primarily in extracellular fluid
Intranasal: 10-20%; Intravenous: 100%; Sublingual: 5-10%; Oral: <1% (extensive first-pass metabolism).
100% by intravenous route; Not bioavailable orally
No dose adjustment required for renal impairment. Insufficient data for GFR-based modifications.
No adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce dose by 50%. For GFR <10 m L/min: avoid use.
No specific Child-Pugh based dose adjustments available. Use with caution in severe hepatic impairment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Intranasal: <50 kg: 1 spray (1.5 mg) into one nostril; ≥50 kg: same as adult. May repeat once after 30-60 minutes.
0.2 mg/kg intravenously, repeat every 2 hours as needed. Maximum dose: 10 mg.
No specific dose adjustment recommended. Monitor for adverse effects due to potential comorbidities and concomitant medications.
Initial dose of 10 mg intravenously, titrate cautiously due to increased sensitivity. Maximum single dose: 40 mg.
WARNING: HYPONATREMIA and SEIZURES. Desmopressin can cause severe hyponatremia, which may be life-threatening if not promptly treated. Seizures have been reported. Risk is increased in patients with fluid or electrolyte imbalances, cystic fibrosis, heart failure, or those on medications that increase hyponatremia risk.
None.
Hyponatremia and seizures: monitor serum sodium in patients at high risk; avoid excessive fluid intake.,Cardiovascular: caution in patients with coronary artery disease or hypertension, as increased blood pressure or ischemia may occur.,Fluid retention: avoid in patients with conditions predisposing to fluid overload (e.g., heart failure).,Thrombotic events: use cautiously in patients with risk factors for thrombosis (e.g., advanced atherosclerosis, smoking, oral contraceptives).,Renal impairment: dose reduction may be necessary; monitor renal function.,Cystic fibrosis: increased risk of hyponatremia and seizures.,Hypersensitivity: anaphylactic reactions reported; discontinue if allergic reaction occurs.
Monitor fluid and electrolyte balance to avoid water intoxication and hyponatremia.,Use with caution in patients with coronary artery disease, hypertension, or renal impairment.,May cause anaphylaxis or hypersensitivity reactions.
Hypersensitivity to desmopressin or any component of the formulation,Moderate to severe renal impairment (creatinine clearance <50 m L/min),Hyponatremia or history of hyponatremia,Primary nocturnal enuresis in patients with polydipsia or excessive fluid intake,Uncontrolled hypertension,Coronary artery disease of any cause,Thrombotic states (e.g., deep vein thrombosis, pulmonary embolism),Patients on medications that increase hyponatremia risk (e.g., SSRIs, NSAIDs, diuretics) unless closely monitored
Hypersensitivity to lypressin or any component,Severe renal impairment (anuria),Chronic nephritis with nitrogen retention
Avoid high-sodium foods that may increase thirst and fluid intake. Grapefruit juice may increase desmopressin absorption (monitor for enhanced effect). No other significant food interactions.
No significant food interactions. However, avoid excessive water intake and alcohol, which can affect ADH secretion.
Desmopressin is a synthetic analog of vasopressin. Available data in pregnant women are insufficient to determine drug-associated risk of major birth defects and miscarriage. In animal studies, no teratogenic effects were observed at doses up to 100 times the human dose. Desmopressin does not cross the placenta in significant amounts due to its large molecular weight and enzymatic degradation. During the first trimester, theoretical risk of hyponatremia and seizures in the fetus if maternal hyponatremia occurs. In the second and third trimesters, increased uterine contractility has been reported in some cases. Overall, desmopressin is considered low risk, but caution is advised.
Diapide is contraindicated in pregnancy due to known teratogenic effects. First trimester exposure is associated with increased risk of congenital malformations, particularly cardiovascular and neural tube defects. Second and third trimester exposure may cause fetal hyperinsulinemia, macrosomia, and neonatal hypoglycemia.
Desmopressin is excreted into human breast milk in very small amounts. The milk-to-plasma (M/P) ratio is not well established but is estimated to be less than 0.1 based on available data. At therapeutic doses, it is unlikely to affect the nursing infant. However, caution is recommended due to potential for water retention and hyponatremia in the infant. Use only if clearly needed.
Excretion into breast milk is unknown; however, due to potential for adverse effects in the nursing infant (e.g., hypoglycemia), breastfeeding is not recommended during therapy. M/P ratio: not determined.
No standard dose adjustments for pregnancy are required. However, increased clearance of desmopressin during pregnancy may necessitate dose titration based on clinical response and serum sodium levels. For central diabetes insipidus, doses may need to be increased in the second and third trimesters. Close monitoring is essential.
No safe dose established in pregnancy. If use is unavoidable during pregnancy, dose adjustment is not recommended due to teratogenicity; alternative therapy should be employed.
Stimate (desmopressin acetate) is a synthetic analog of vasopressin used for diabetes insipidus and hemophilia A/von Willebrand disease. It causes vasoconstriction and platelet aggregation; monitor for hyponatremia, especially in elderly or patients with fluid intake >2 L/day. Avoid in patients with severe renal impairment (e GFR <50 m L/min). For nocturnal enuresis, restrict fluid 1 hour before and 8 hours after dose. Needs no refrigeration, but store at room temperature (15-30°C).
Diapid (desmopressin) is used for central diabetes insipidus and nocturnal enuresis. Monitor for hyponatremia, especially in elderly or patients with fluid/electrolyte imbalance. Avoid overhydration. Intranasal formulation may cause rhinitis or epistaxis.
Do not refrigerate; store at room temperature.,Limit fluid intake for 8 hours after dosing to prevent water intoxication.,Report headache, nausea, confusion, or rapid weight gain (signs of hyponatremia).,If used for bedwetting, take last dose at bedtime and empty bladder before sleep.,Do not use with alcohol or other vasopressin analogs without doctor approval.
Use exactly as prescribed; do not exceed dose to avoid water intoxication.,Limit fluid intake to prevent hyponatremia (symptoms: headache, nausea, confusion).,For intranasal spray, gentle priming and alternating nostrils each dose.,Report signs of low sodium: severe headache, vomiting, muscle cramps, drowsiness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about STIMATE (NEEDS NO REFRIGERATION) vs DIAPID, answered by our medical review team.
STIMATE (NEEDS NO REFRIGERATION) is a Antidiuretic Hormone Analog that works by Desmopressin is a synthetic analogue of vasopressin (antidiuretic hormone) that increases cyclic AMP levels in renal collecting duct cells, enhancing water reabsorption and concentrating urine. It also raises plasma levels of von Willebrand factor and factor VIII by stimulating release from endothelial stores.. DIAPID is a Antidiuretic Hormone Analog that works by Diapid (lypressin) is a synthetic analog of vasopressin that acts as an antidiuretic by increasing water reabsorption in the renal collecting ducts via V2 receptor activation. It also has mild vasopressor activity via V1 receptor stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between STIMATE (NEEDS NO REFRIGERATION) and DIAPID depend on the specific clinical indication. These are both Antidiuretic Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of STIMATE (NEEDS NO REFRIGERATION) is: Intranasal: 1 spray (1.5 mg) into one nostril; may repeat once after 30-60 minutes if needed. Not to exceed 2 doses per bleeding episode.. The standard adult dose of DIAPID is: Intravenous bolus of 20 mg followed by 20-40 mg every 2-4 hours as needed. Maximum single dose: 80 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between STIMATE (NEEDS NO REFRIGERATION) and DIAPID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. STIMATE (NEEDS NO REFRIGERATION) is classified as Category C. Desmopressin is a synthetic analog of vasopressin. Available data in pregnant women are insufficient to determine drug-associated risk of major birth defects and miscarriage. In an. DIAPID is classified as Category C. Diapide is contraindicated in pregnancy due to known teratogenic effects. First trimester exposure is associated with increased risk of congenital malformations, particularly cardi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.